BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:cemacabtagene ansegedleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of cemacabtagene ansegedleucel\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06500273-10855@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:cemacabtagene ansegedleucel: Phase 2 readout est. (NCT06500273)
DESCRIPTION:cemacabtagene ansegedleucel\, phase 2\, Large B-Cell Lymphoma.\
 nStudy: Consolidation of First-Line MRD+ Remission With Cema-cel in Patien
 ts With LBCL\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cemacabtagene-ansegedleucel#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06500273
URL:https://assetmemo.bio/drug/cemacabtagene-ansegedleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04416984-10855@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:cemacabtagene ansegedleucel: Phase 1/2 readout est. (NCT04416984)
DESCRIPTION:cemacabtagene ansegedleucel\, phase 1/2\, Large B-Cell Lymphoma
 .\nStudy: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cell
 s in Adults With Relapsed/Refractory Large B Cell Lymphoma\, Chronic Lymph
 ocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)\nEstimated primary
  completion: February 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cemacabtagene-ansegedleucel#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04416984
URL:https://assetmemo.bio/drug/cemacabtagene-ansegedleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
